The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus
Meiyuan Dong,Huiling Chen,Song Wen,Yue Yuan,Liling Yang,Dongxiang Xu,Ligang Zhou
DOI: https://doi.org/10.2147/DMSO.S399343
2023-02-16
Abstract:Meiyuan Dong, 1, 2 Huiling Chen, 2 Song Wen, 2 Yue Yuan, 2 Liling Yang, 2 Dongxiang Xu, 2 Ligang Zhou 1– 3 1 Graduate School of Hebei Medical University, Shijiazhuang, People's Republic of China; 2 Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, People's Republic of China; 3 Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai Pudong Hospital, Fudan University, Shanghai, People's Republic of China Correspondence: Ligang Zhou, Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People's Republic of China, Tel +8613611927616, Email Hyperuricemia is a common comorbidity in patients with type 2 diabetes mellitus (T2DM), as insulin resistance (IR) or hyperinsulinemia is associated with higher serum uric acid (SUA) levels due to decreased uric acid (UA) secretion, and SUA vice versa is an important risk factor that promotes the occurrence and progression of T2DM and its complications. Growing evidence suggests that sodium-glucose cotransporter 2 inhibitors (SGLT-2i), a novel anti-diabetic drug initially developed to treat T2DM, may exert favorable effects in reducing SUA. Currently, one of the possible mechanisms is that SGLT2i increases urinary glucose excretion, probably inhibiting glucose transport 9 (GLUT9)-mediated uric acid reabsorption in the collecting duct, resulting in increased uric acid excretion in exchange for glucose reabsorption. Regardless of this possible mechanism, the underlying comprehensive mechanisms remain poorly elucidated. Therefore, in the present review, a variety of other potential mechanisms will be covered to identify the therapeutic role of SGLT-2i in hyperuricemia. Keywords: hyperuricemia, uric acid, type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibitors Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by chronic hyperglycemia and is considered one of the main global causes of morbidity and mortality. 1 Serum uric acid (SUA) is the final product of purine metabolism by xanthine oxidoreductase (XO), and hyperuricemia is caused by abnormal purine metabolism. Patients with an increase in SUA concentration are at risk for diabetes, metabolic syndrome (MetS), and other related symptoms. In an observational study, the researchers eventually enrolled 46,561 eligible participants in Taiwan's Health Examination Registration System from 2013 to 2015, and found that SUA is an important predictor of the risk of MetS, DM and hypertension in adults, especially in men. 2 In recent decades, a great deal of studies has demonstrated that hyperuricemia is an independent risk factor for CVD, as well high UA promotes insulin resistance; it is also associated with atrial fibrillation (Malhotra, #26), heart failure (HF), major adverse cardiovascular events (MACE) such as death, infarction, stroke, glomerular damage, tubulointerstitial fibrosis and chronic kidney disease (CKD). 3–7 In a meta-analysis based on observational cohort studies, it is demonstrated that SUA is an independent risk factor for CKD, even without diabetes. 8 Given the various detrimental complications that could be associated with hyperuricemia, reducing SUA may be beneficial for T2DM patients as they may be at a higher risk of microvascular and cardiovascular diseases. Therefore, reducing SUA levels is necessary. Sodium-glucose cotransporter 2 (SGLT-2) is predominantly expressed in kidney segments 1 and 2 of the proximal convoluted tubules' apical membrane. 9 Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are a novel family of medications used to treat T2DM by inhibiting SGLT-2 in the renal proximal tubules, which is responsible for 90% of renal glucose reabsorption. 10 This mechanism is glucose-dependent and has nothing to do with the efficacy or availability of insulin. SGLT2I leads to an increase in urine glucose that is accompanied by osmotic diuresis and a decrease in blood pressure. 11 In addition to the anti-diabetic effects, weight loss has also been observed in patients receiving SGLT-2i therapy. In the cardiovascular outcome trial (CVOTS), SGLT2i has been shown to reduce major adverse cardiovascular events (MACE) and hospitalization for heart failure, and is associated with slow progression of kidney disease and lower incidence of renal end points, and these effects appear to be independent of hypoglycemia effects. 12,13 In addition, the latest clinical trials have shown that SUA levels could be reduced by SGLT2i. 10,14 However, the exact mechanism underpin is to be determined. Therefore, in this review, we will talk about the possible mechanisms of SGLT2i in lowering the SUA lev -Abstract Truncated-
endocrinology & metabolism